The 2018 CPhI Pharma Awards, which recognise excellence in pharma, selected 17 winners from over 250 entries. The awards are among the most prestigious in the industry, celebrating thinkers and creators breaking new ground and strongly advocating companies committed to driving the industry forward.
The 2018 winners are:
API Development
Ipca Labs Limited – Artemisinin
Formulation
MiVital AG – Micelle Inside Solubilisation
Excipients
Merck – Parteck MXP Excipient
The former AkzoNobel Specialty Chemicals has relaunched as Nouryon and has a new brand and purpose to reflect its goal of unleashing its full potential as an independent global speciality chemicals leader.
The company partnered with Globrands on the naming process, with VBAT on the brand design and with VIM Group on the global rebranding process. The new branding is already visible on Nouryon’s digital channels. Packaging and signage will be changed gradually over the course of the coming year.
The US Institute for In Vitro Sciences (IIVS) is teaming up with chemicals giant BASF and cosmetics company Givaudan to validate an improved skin sensitisation reactivity method to address the needs of toxicologists and regulators.
Speciality chemicals world leader, Clariant, has started the construction of the first large-scale commercial ‘sunliquid’ plant for the production of cellulosic ethanol made from agricultural residues.
At the flagship facility, the sunliquid technology developed by Clariant is being used on an industrial scale for the first time.
Multinational chemicals giant, Dow Chemical Company and Japan’s Shin-Etsu Chemical Company are investing in their silicones franchises.
Dow’s investment plans include a series of incremental siloxane debottlenecking and efficiency improvement projects over the next three years to increase production at its manufacturing facilities around the world. It will also build a new hydroxyl functional siloxane polymer plant in Carrollton, Kentucky, US, which will increase Dow’s polymer capacity in the US by 65%.
Boehringer Ingelheim (BI) has started the construction of a new production facility for innovative drugs. The new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches.
The research-driven pharmaceutical company is investing €85 million (US$99.3 million) in Ingelheim, focusing on modern and flexible production.
Global speciality chemicals company Clariant has announced an updated strategy for its speciality chemicals segment, alongside a collaboration with SABIC on high performance materials.
By 2021, it will combine its Additives and high value Masterbatches (colour, high temperature resins and health care) businesses into a High Performance Materials division, with parts of SABIC’s Specialties business. It will also divest its remaining Plastics & Coatings Business, including Pigments, standard Masterbatches and Medical Specialties.
